Frontiers in PhysiologySystems BiologyPeer-reviewed journal article
Exploring the extracellular regulation of the tumor angiogenic interaction network using a systems biology model
Abstract
Tumor angiogenesis is regulated by pro- and anti-angiogenic factors. Anti-angiogenic agents target the interconnected network of angiogenic factors to inhibit neovascularization, which subsequently impedes tumor growth. Due to the complexity of this network, optimizing anti-angiogenic cancer treatments requires detailed knowledge at a systems level. In this study, we constructed a tumor tissue-based model to better understand how the angiogenic network is regulated by opposing mediators at the extracellular level. We consider the network comprised of two pro-angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF2), and two anti-angiogenic factors: thrombospondin-1 (TSP1) and platelet factor 4 (PF4). The models prediction of angiogenic factors distribution in tumor tissue reveals the localization of different factors and indicates the angiogenic state of the tumor. We explored how the distributions are affected by the secretion of the pro- and anti-angiogenic factors, illustrating how the angiogenic network is regulated in the extracellular space. Interestingly, we identified a counterintuitive result that the secretion of the anti-angiogenic factor PF4 can enhance pro-angiogenic signaling by elevating the levels of the interstitial and sur-face-level pro-angiogenic species. This counterintuitive situation is pertinent to the clinical setting, such as the release of anti-angiogenic factors in platelet activation or the administration of exogenous PF4 for anti-angiogenic therapy. Our study provides mechanistic insights into this counterintuitive result and highlights the role of heparan sulfate proteoglycans in regulating the interactions between angiogenic factors. This work complements previous studies aimed at understanding formation of angiogenic complexes in tumor tissue and helps in the development of anti-cancer strategies targeting angiogenesis.
- Citations
- 13
- FWCI
- 0.83
- Field percentile
- top 31%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment
Ding Li, Stacey D. Finley·Integrative BiologyPeer-reviewed·Apr 1, 2018
- Fibroblast growth factor is predicted to dominate MAPK activation by pro-angiogenic factors
Min Song, Stacey D. Finley·BMC Systems BiologyPeer-reviewed·Dec 1, 2018
- Mechanistic Modeling Quantifies The Influence Of Tumor Growth Kinetics On The Response To Anti-Angiogenic Treatment
Thomas D. Gaddy, Qianhui Wu, … Stacey D. Finley·PLoS Computational BiologyPeer-reviewed·Dec 21, 2017
- Phased affinity-controlled delivery of vascular endothelial growth factor, fibroblast growth factor-2, and platelet derived growth factor enhances in vitro angiogenesis
Justin E. Svendsen, Chandler L. Asnes, … Marian H. Hettiaratchi·Journal of Controlled ReleasePeer-reviewed·Jul 14, 2026
- Cross-family interactions of vascular endothelial growth factors and platelet-derived growth factors on the endothelial cell surface: A computational model
Yunjeong Lee, Yingye Fang, … P. I. Imoukhuede·bioRxiv·Feb 27, 2025
- Multiscale modeling of tumor adaption and invasion following anti-angiogenic therapy
Colin G. Cess, Stacey D. Finley·Computational and Systems OncologyPeer-reviewed·Feb 21, 2022